Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
appeal, appealed, appellate, argument, aspinall, belonging, Boston, charter, Codification, CODM, context, CUP, denial, deprioritized, derogation, diligence, dossier, EEA, expenditure, extortion, fingerstick, footprint, grandfathering, impede, insight, inter, Interagency, Israel, KKR, leasehold, lelio, lodge, Maker, malware, mandatory, manual, mara, marmora, mcmahon, MetaGene, negligible, NIST, OMNImet, organizational, outsourced, oversee, oxycodone, Parliament, penetration, petition, powering, proceed, PTO, QMSR, questionnaire, ran, ransomware, rebate, receivership, referenced, reside, robert, rolling, shortened, Silicon, Silvergate, Stefano, style, supervisory, SUREQUICK, survive, Taiwan, theft, tool, Unbilled, unpatentable, Valley, virtue, VP, withdrew
Removed:
accompany, Accountant, advertise, aim, allocate, allocation, anticipation, arise, ascribed, attack, brand, buffer, Center, Citigroup, combined, compound, conclude, confirmed, consumed, contingency, continuously, contractually, counseling, covid, deductible, deducting, deem, deposited, discounted, disposable, diverse, downturn, DRM, easier, EIA, empower, encourage, enzyme, epidemic, equitable, escrow, Evercore, exemplify, exercisable, expertise, extraction, fluctuating, generating, handle, harmonization, holdback, ill, incapacitated, incorporate, inherently, instrumentation, interpret, Latino, legacy, leverage, Lisa, lose, marketable, men, merger, Mine, Morgan, nasopharyngeal, Nibauer, nonessential, Northampton, obligated, Occupational, OMNImetTM, oropharyngeal, overhaul, principally, projected, proportion, quick, reclassification, regime, rent, returning, safeguard, sanitation, setting, sex, spear, specialist, stay, stick, strive, Supplementary, telework, thermometer, Township, trained, treated, underwriting, undetermined, Unresolved, updated, uptake, UrSure, voyeur, young
Financial report summary
?Risks
- Risks Relating to Products, Marketing and Sales
- Risks Relating to the Company's Industry, Business and Strategy
- Risks Relating to the Company's Reliance on Third Parties
- Risks Relating to Intellectual Property
- Risks Relating to the Economy, Company Financial Results, Investments, Credit Facilities and Need for Financing
- Risks Relating to the Company's Common Stock
- Risks Relating to Products, Marketing and Sales
- The Company's Future Success Depends Upon Market Acceptance of its Existing and Future Products and Service Offerings.
- Marketing of the Company's COVID-19 Tests and Collection Kits Under EUAs from the FDA Is Subject To Certain Limitations and the Company Is Required To Maintain Compliance with the Terms of the EUA, Among Other Things, and the Continuance of the EUAs Is Subject To Government Discretion.
- If Acceptance and Adoption of Oral Fluid Testing and Collection Products Does Not Continue, the Company's Future Results May Suffer.
- The Company Expects to Face Increasing Competition From Other Providers of Diagnostic Tests, Sample Collection Products and Molecular Laboratory Services.
- The Company's Product Sales Cycles Can be Lengthy, and May Depend on Public Funding, Which Can Cause Variability and Unpredictability in the Company's Operating Results.
- The Company's Inability To Expand International Sales Could Adversely Affect its Business and Results of Operations.
- The Company's International Presence May Increase Its Risks and Expose Its Business to Regulatory, Cultural or Other Restraints.
- The Company's Inability to Manufacture Products in Accordance with Applicable Specifications, Performance Standards or Quality Requirements Could Adversely Affect Its Business.
- The Company's Business Will Suffer if It Does Not Effectively Manage Challenges to Its Manufacturing Processes and It May be Unable to Successfully Scale-Up Manufacturing of Its Products in Sufficient Quality and Quantity to Meet Demand, Which Would Negatively Impact Revenue Expectations.
- The Company's Business Results Depend on Its Ability to Manage Disruptions in Its Domestic and Global Supply Chains and Distribution Channels.
- Certain of the Company's Products Depend on Components From a Sole-Source Supplier, the Loss of Which Would Cause the Company to be Unable to Deliver Such Products.
- The Company's U.S. Government Contracts May Affect Its Intellectual Property Rights.
- The Company's U.S. Government Contracts and Related Administrative Processes Are Subject to Audits and Cost Adjustments by the Federal Government.
- Risks Relating to the Company's Industry, Business and Strategy
- Consolidation in the Healthcare Industry Could Adversely Affect the Company's Future Revenues and Operating Results.
- The Company's Research, Development and Commercialization Efforts May Not Succeed and Its Competitors May Develop and Commercialize More Effective or Successful Offerings.
- Customer Concentration Creates Risk for the Company's Business.
- Acquisitions or Investments May Not Generate the Expected Benefits and Could Disrupt the Company's Ongoing Business, Distract Its Management, Increase Its Expenses and Adversely Affect Its Business.
- The Company's Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints.
- Changes in Healthcare Regulation Could Affect the Company's Revenues, Costs and Financial Condition.
- New or Changed Testing Guidelines Could Affect Sales of the Company's Diagnostic Products.
- Reductions in Government Funding and Research Budgets Could Adversely Affect the Company's Business and Financial Results.
- Risks Relating to the Company's Reliance on Third Parties
- The Company's Failure to Maintain Existing Distribution Channels, or Develop New Distribution Channels, May Result in Lower Revenues.
- The Company May Need Strategic Partners to Assist in Developing and Commercializing Some of Its Products.
- Risks Relating to Intellectual Property
- The Company's Success Depends on Its Ability to Protect Its Proprietary Technology.
- The Company May Become Involved in Intellectual Property Disputes, Which Could Increase Its Costs and Limit or Eliminate Its Ability to Sell Products, Provide Services or Use Certain Technologies.
- The Need to Obtain Regulatory Approvals, Clearances, Authorizations or Certifications Could Increase the Company's Costs and Adversely Affect Its Financial Performance.
- Failure to Comply With FDA or Other Regulatory Requirements May Require the Company to Suspend Production or Sale of Its Products or Institute a Recall Which Could Result in Higher Costs and a Loss of Revenues.
- The Company's Inability to Respond to Changes in Regulatory Requirements Could Adversely Affect Its Business.
- The Company Is Subject to Numerous Government Regulations in Addition to FDA Requirements, Which Could Increase the Company's Costs and Affect Its Operations.
- Failure to Comply With Privacy, Security and Breach Notification Regulations May Increase the Company's Costs.
- FDA Regulation of Laboratory-Developed Tests and Genetic Testing Could Affect Demand For the Company's Products.
- Risks Relating to the Economy, the Company's Financial Results, Investments, Credit Facilities and Need for Financing
- Rising Inflation Rates Could Negatively Impact the Company's Revenues and Profitability if Increases in the Prices of Its Products or a Decrease in Consumer Spending Results in Lower Sales. In Addition, if the Company's Costs Increase and the Company Is Not Able to Pass Along These Price Increases to Its Customers, Its Net Income Would Be Adversely Affected, and the Adverse Impact May Be Material.
- Changes in Foreign Currency Exchange Rates Could Negatively Affect the Company's Operating Results.
- Risks Relating to the Company's Common Stock
- The Company's Stock Price Could Continue to be Volatile.
- Future Sales of the Company's Common Stock by Existing Stockholders, Executive Officers or Directors Could Depress the Market Price of Its Common Stock and Make It More Difficult for the Company to Sell Stock in the Future.
- Because the Company Does Not Intend to Pay Cash Dividends on Its Common Stock, an Investor in the Company's Common Stock Will Benefit Only if the Its Common Stock Appreciates in Value.
- The Company May Face Product Liability Claims for Injuries Resulting From the Use of Its Products.
- Performance of the Company's Products May Affect Its Revenues, Stock Price and Reputation.
- The Company's Ability to Sell Products Could be Adversely Affected by Competition From New and Existing Products and Services.
- Failure to Achieve the Company's Financial and Strategic Objectives Could Have a Material Adverse Impact on Its Business Prospects.
- If the Company Fails To Establish and Maintain Proper And Effective Internal Control Over Financial Reporting, Its Operating Results and Its Ability to Operate Its Business Could Be Harmed.
- If the Company Loses Key Personnel or Is Unable to Attract and Retain Qualified Personnel as Necessary, Its Business Could be Harmed.
- Increases in Demand for the Company's Products and Services Could Require It to Expend Considerable Resources or Harm Its Customer Relationships if It Is Unable to Meet That Demand.
- The Company Relies on Information Technology in Its Operations and Any Material Failure, Inadequacy, Interruption or Security Breach of that Technology Could Harm Its Ability to Efficiently Operate Its Business.
- Cybersecurity Incidents and Other Disruptions Could Compromise the Company's Information, Expose It to Liability and Harm Its Reputation and Business.
- Federal and State Laws Pertaining to Healthcare Fraud and Abuse Could Adversely Affect the Company's Business, Financial Condition and Results of Operations.
- The Company May Experience Fluctuations in Its Financial Results or Fail to Meet Its Financial Projections.
- The Company May Require Future Additional Capital.
- Conditions in the Banking System and Financial Markets, Including the Failure of Banks and Financial Institutions, Could Have an Adverse Effect on the Company's Operations and Financial Results.
- Terrorist Attacks, Natural Disasters, Public Health Crises, Political Unrest or Other Catastrophic Events Outside of the Company's Control May Adversely Affect Its Business.
- The Ongoing Conflict Between Russia and Ukraine, and the Israel-Hamas War, and the Related Implications Could Have a Material Adverse Effect on the Company's Business And Results Of Operations.
- Future Sales of Shares of the Company's Common Stock Could Adversely Affect the Trading Price of Its Common Stock and Its Ability to Raise Funds in New Equity Offerings.
Management Discussion
- The table below shows a summary of total consolidated net revenues (dollars in thousands) for the years ended December 31, 2023 and 2022.
- (1)Includes HIV and HCV product revenues.
- (2)Includes Genomics, Microbiome and Novosanis product revenues.